A Study on Etrasimod in Adults With Patchy Hair Loss
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study, With a 28-Week Open-Label Extension, to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Alopecia Areata
Category & Conditions: Immune System Diseases and Conditions
Medicine: ETRASIMOD
ClinicalTrials.gov Identifier (NCT): NCT04556734
Protocol ID: C5041008
Open Plain Language Summary Result:
Click here